Wheeler R H, Spencer S, Buchsbaum D, Robert F
Department of Medicine, Comprehensive Cancer Center, University of Alabama at Birmingham, 35233-6382, USA.
Curr Opin Oncol. 1999 May;11(3):187-90. doi: 10.1097/00001622-199905000-00009.
The overall survival of patients with squamous cell cancer of the head and neck has not significantly improved over the past 2 decades. Preclinical studies suggest that combining a monoclonal antibody to the epidermal growth factor receptor with irradiation or chemotherapy agents active in squamous cell cancer of the head and neck could increase treatment efficacy. Completed phase I studies have shown these combinations to be both feasible and tolerable. Phase III studies are now beginning to establish firmly the efficacy of this innovative new approach.
在过去20年中，头颈部鳞状细胞癌患者的总体生存率并未得到显著改善。临床前研究表明，将针对表皮生长因子受体的单克隆抗体与对头颈部鳞状细胞癌有效的放疗或化疗药物联合使用，可能会提高治疗效果。已完成的I期研究表明，这些联合治疗方法既可行又可耐受。III期研究现正开始切实确立这种创新新方法的疗效。
